What is Crossject?
Crossject Société Anonyme is a French biotechnology firm specializing in the development of needle-free injection systems. Its flagship technology, ZENEO, is designed to simplify the administration of self-injectable medications, addressing critical needs in emergency and chronic care. The company's robust pipeline includes life-saving treatments for conditions such as epileptic seizures, opioid overdoses, severe asthma, anaphylactic shock, and migraines. By eliminating the need for traditional needles, Crossject is effectively lowering barriers to patient compliance and improving outcomes in high-stakes medical scenarios. The company operates at the intersection of medical device innovation and pharmaceutical efficacy, positioning itself as a critical partner for healthcare providers and patients requiring rapid, reliable drug delivery.
How much funding has Crossject raised?
Crossject has raised a total of $60.4M across 6 funding rounds:
Debt
$12M
Unspecified
$7.6M
Multiple Rounds
$23.5M
Stock/Share Issuance
$17.3M
Debt (2020): $12M, investors not publicly disclosed
Unspecified (2024): $7.6M led by Agence nationale de la recherche ANR
Stock/Share Issuance (2025): $6.4M, investors not publicly disclosed
Other Financing Round (2025): $11.3M featuring Biomedical Advanced Research and Development Authority (BARDA
Debt (2025): $5.8M backed by Vatel Capital
Stock/Share Issuance (2026): $17.3M, investors not publicly disclosed
Key Investors in Crossject
Biomedical Advanced Research and Development Authority (BARDA)
BARDA enhances public health security by facilitating the development of innovative medical countermeasures, partnering with innovators to bring promising therapeutics from preclinical stages to FDA approval.
Vatel Capital
Vatel Capital is a French financial firm specializing in wealth management and tax-efficient investment strategies, providing personalized financial planning to support growth-oriented enterprises.
Agence nationale de la recherche ANR
The ANR is the French national agency responsible for funding project-based research across scientific disciplines, supporting sustainable development and innovation in public health and engineering.
What's next for Crossject?
With the recent influx of capital, Crossject is well-positioned to advance its clinical pipeline and scale its manufacturing capabilities for the ZENEO platform. The strategic focus will likely shift toward securing regulatory approvals for its late-stage candidates, including treatments for acute adrenal crisis and rheumatoid arthritis. Furthermore, the company is expected to leverage its partnerships with public health entities to expand its footprint in the global market, ensuring that its needle-free delivery systems become a standard of care for emergency medical countermeasures. As the firm transitions into a more mature operational phase, the emphasis will remain on clinical validation and the commercialization of its diverse therapeutic portfolio.
See full Crossject company page
